Robert Francomano
Plus aucun poste en cours
Fortune : 33 724 $ au 31/05/2024
Historique de carrière de Robert Francomano
Anciens postes connus de Robert Francomano
Sociétés | Poste | Début | Fin |
---|---|---|---|
SELLAS LIFE SCIENCES GROUP, INC. | Corporate Officer/Principal | 14/03/2022 | 31/03/2024 |
STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | 01/09/2016 | 01/12/2021 |
Formation de Robert Francomano
Siena College | Undergraduate Degree |
University of Albany | Masters Business Admin |
Statistiques
Internationale
Etats-Unis | 5 |
Opérationnelle
Corporate Officer/Principal | 2 |
Undergraduate Degree | 1 |
Masters Business Admin | 1 |
Sectorielle
Health Technology | 3 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
SELLAS LIFE SCIENCES GROUP, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
- Bourse
- Insiders
- Robert Francomano
- Expérience